Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Indian Sun's generic AD drug

The US FDA has approved Indian company Sun Pharma's generic equivalent of Forest Laboratory's Alzheimer's disease treatment Namenda 

The US Food and Drug Administration (FDA) has approved Indian company Sun Pharma's Abbreviated New Drug Application (ANDA) to market a generic equivalent of Forest Laboratory's Alzheimer's disease (AD) treatment Namenda (memantine). Sun will receive 180 days of sales exclusivity on the drug which will be sold in 5mg and 10mg tablets.

The Mumbai-based company said that 5mg and 10mg strengths of memantine have combined annual sales of around $1.2bn in the US.

Memantine is the first in a novel class of Alzheimer's disease medications, which work by acting on the glutamatergic system, blocking NMDA glutamate receptors.

Memantine is also sold by Merz as Akatinol, by Lundbeck as Ebixa and Abixa and by Unipharm as Memox.

6th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics